Alzheimer’s disease treatments are evolving, with newer therapies aiming to help people maintain memory and independence for longer.
- Leqembi is designed for people with the earliest stages of Alzheimer’s disease
- Early diagnosis is becoming increasingly important as disease-modifying therapies become available
- Amyloid-targeted treatments are reshaping the future of Alzheimer’s care
Can a medicine help people with Alzheimer’s disease hold on to their memories for a little longer? That question matters to millions of families worldwide.
More than 55 million people are currently living with dementia, and Alzheimer’s disease is responsible for most of these cases. For patients and caregivers, even a modest delay in memory loss can mean more time for conversations, routines, and independence.
New findings presented at the Alzheimer’s Association International Conference (AAIC) 2026 suggest that Leqembi, an Alzheimer’s drug used in the earliest stages of the disease, may help many patients remain stable for longer.
Researchers reported that 75.9% of patients remained clinically stable, while 6.6% improved by one stage of disease after treatment over an average follow-up of 17 months. Together, nearly 83% either remained stable or improved.
While the findings are preliminary, they offer an encouraging glimpse into a future where Alzheimer’s disease may become a condition that can be slowed for some people rather than simply managed.
Advertisement
Who Can Take Leqembi for Early Alzheimer’s Disease?
Leqembi (lecanemab) is approved for adults with mild cognitive impairment (MCI) due to Alzheimer’s disease and those with mild Alzheimer’s dementia. These are the earliest stages of the disease, when memory changes begin to affect everyday life.
Unlike older Alzheimer’s medicines that mainly help manage symptoms, Leqembi targets amyloid-beta, a protein that forms plaques in the brain. Scientists believe these plaques contribute to the disease process. However, Leqembi is not a cure and does not restore memories that have already been lost (1✔ ✔Trusted Source
Lecanemab in Early Alzheimer’s Disease
Advertisement
How Much Did Leqembi Help Patients in Real-World Treatment?
The LEADER study was designed to understand how Leqembi performs in everyday clinical practice rather than in the highly controlled environment of a clinical trial.
- 75.9% of patients remained clinically stable.
- 6.6% improved by one stage of disease.
- Nearly 83% remained stable or improved.
- Average follow-up duration was 17 months.
Researchers have not yet reported the total number of participants. The study is a multicenter, retrospective analysis conducted across 13 U.S. sites using de-identified medical records and healthcare professional surveys. Importantly, the findings have not yet been published in a peer-reviewed journal and therefore should be considered preliminary until additional details become available (2✔ ✔Trusted Source
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
).
Importantly, these findings are consistent with the earlier Clarity AD clinical trial involving 1,795 participants, which found that Leqembi slowed cognitive and functional decline by 27% over 18 months compared with placebo in people with early Alzheimer’s disease.
Advertisement
Why Does Amyloid Buildup Matter in Alzheimer’s Disease?
Amyloid plaques are sticky protein deposits that build up between brain cells over time. Researchers believe they may interfere with communication between neurons and contribute to inflammation in the brain.
Although scientists continue to investigate exactly how amyloid contributes to Alzheimer’s disease, reducing plaque buildup remains one of the most actively studied treatment approaches worldwide. Leqembi is one of several therapies that reflects a growing shift toward treating the underlying biology of Alzheimer’s disease rather than focusing only on symptoms.
What Are the Risks and Side Effects of Leqembi?
Like all medicines, Leqembi comes with risks that patients and caregivers should understand before starting treatment.
The most important safety concern is amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or small areas of bleeding. Doctors monitor patients using MRI scans before and during treatment. People taking blood-thinning medications may require additional evaluation before treatment begins.
Treatment decisions should always be made with a neurologist who can help patients weigh the potential benefits and risks based on their individual circumstances.
What Does Leqembi Mean for the Future of Alzheimer’s Care?
| Question to Ask Your Doctor | Why It Matters |
|---|---|
| Am I in the early stage of Alzheimer’s disease? | Leqembi is intended for people with mild cognitive impairment or mild Alzheimer’s dementia. |
| Have I had amyloid testing? | Treatment eligibility typically requires confirmation of amyloid buildup in the brain. |
| Will I need MRI monitoring? | MRI scans help doctors detect ARIA during treatment. |
| What benefits and risks should I expect? | Understanding realistic expectations supports informed decision-making. |
Alzheimer’s disease remains one of the world’s greatest health challenges, affecting millions of families every year. While Leqembi is not a cure, it represents an important shift in how doctors think about the disease, moving from treating symptoms to potentially slowing its progression in selected patients.
For patients and caregivers, the message is simple: do not ignore early memory changes. Speaking with a healthcare professional sooner rather than later may open the door to new treatment options as science continues to advance (3✔ ✔Trusted Source
Dementia
Every new discovery brings researchers one step closer to a future where living with Alzheimer’s disease means having more time for conversations, family moments, and independence. For many families around the world, that possibility alone is worth paying attention to.
Frequently Asked Questions
Q: What is Leqembi used for?
A: Leqembi is used to treat adults with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia.
Q: Can Leqembi help people with Alzheimer’s keep their memory longer?
A: Leqembi may help slow disease progression in some people with early Alzheimer’s disease, potentially helping them maintain memory and daily functioning for longer.
Q: Is Leqembi a cure for Alzheimer’s disease?
A: No. Leqembi is not a cure and does not reverse existing memory loss. It is designed to slow disease progression in eligible patients.
Q: What are the side effects of Leqembi?
A: The most significant side effect is amyloid-related imaging abnormalities (ARIA), which can involve brain swelling or small areas of bleeding that require MRI monitoring.
Q: When should I talk to a doctor about memory problems?
A: Anyone experiencing persistent memory changes, confusion, or difficulty performing everyday activities should seek medical advice, particularly if symptoms are worsening over time.
References:
- Lecanemab in Early Alzheimer’s Disease – (https://pubmed.ncbi.nlm.nih.gov/36449413/)
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment – (https://media-us.eisai.com/2026-07-14-LEQEMBI-R-Real-World-LEADER-Study-Presented-at-AAIC-R-2026-Finds-Over-75-of-Early-Alzheimers-Patients-Enrolled-in-the-Study-Remained-Stable-and-Nearly-7-Improved-Over-an-Average-of-17-Months-of-Treatment)
- Dementia – (https://www.who.int/news-room/fact-sheets/detail/dementia)
Source-Medindia